Validation of a Genetic Signature to Predict the Development of Sarcomas

A total of 60 patients will be included in this pilot study:

• Group 1: 20 patients with induced radio sarcoma
• Group 2: 20 patients without primary sarcoma or induced radio sarcoma
• Group 3: 20 patients with primary sarcoma These numbers will make it possible to have preliminary data making it possible to judge the interest of the genetic signature in the prediction of the radiation-induced sarcomas.

Inclusion criteria

• Major patient at the time of initial radiotherapy or diagnosis of primary sarcoma.
• Patient belonging to one of these 3 groups :

Group 1: Patient treated with radiotherapy for cancer other than primary sarcoma and who developed sarcoma (other than osteosarcoma) in the irradiated area.

OR Group 2: Patient who received radiotherapy for more than 5 years and did not develop sarcoma or other secondary cancers OR Group 3: Patient who developed primary sarcoma and who had never been treated with radiotherapy

• Patient who have signed informed consent to participate in the study.
• Affiliation to the social security system.

Exclusion criteria

• Patient unable to understand, read and / or sign informed consent.
• Person benefiting from a protection system for adults (including guardianship and trusteeship)
• Pregnant or lactating woman.
• Patient who participated in the SARI study "Predictive study of sarcomas developed in irradiated territory from the GSF-GETO database (ID-RCB no .: 2011-A01102-39)"